si-544 – A Highly Differentiated Asset in Autoimmunity

  • Best-in-class Kv1.3 blocker

  • Benchmark for safety and tolerability in autoimmune therapy

  • Maintains patient’s full immunocompetence

  • Short treatment course delivers sustained clinical benefit

  • Pipeline drug for autoimmunity

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events